No Data
Kringle Pharma: Full year financial results briefing materials for the fiscal year ending September 2024
Stocks hitting the upper or lower price limit in the afternoon session.
▪︎veru inc <2901> Welsh <3967> Ertes <4051> GMO Financial Gate <4166> Kakkō <4295> Face <4576> De Western Serapitek Research Institute <4884> Kringle Pharma <4935> Liberta <6573> Agile Broadcasting Network <6977> Japan Resistor Manufacturing ▪︎veru inc <9073> Kyojok Transport Trading ※Including temporary upper and lower price limits (indicative value)
Kringle Pharma: Summary of financial results for the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)
Kringle Pharma FY Parent Loss Y756.00M Vs Loss Y854.00M
Kringle Pharma Sees Parent FY Loss Y1.38B
GMO-FG, Kringle, and others
<166A> Taski HD increased dividends, with the current year-end dividend per share at 16.00 yen, up from 15.00 yen. <2342> Trans GG revises its performance forecast, with the current operating profit estimate at a loss of 0.11 billion yen, down from 0.35 billion yen. Dividend forecast revised, with the year-end dividend suspended. <4051> GMO-FG increased dividends, with the previous period's year-end dividend per share at 62.00 yen, up from 52.00 yen. <4168> Yapri revises its performance forecast, with the current operating profit estimate at 0.55 billion yen, up from 0.5 billion yen. <4583> Kaiom revises its performance forecast, with the current revenue estimate at 6.00.
No Data
No Data